APUS Apimeds Pharmaceuticals US, Inc. revenue, earnings and financials
For the quarter ended June 30, 2026, Apimeds Pharmaceuticals US, Inc. reported revenue of n/a, net income of −$20.2M and diluted EPS of −$11.77; for the fiscal year ended December 2025 revenue was n/a.
APUS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$11.9M, net income −$6.00M (margin n/a), EPS −$0.55
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$1.28M, net income −$1.39M (margin n/a), EPS −$0.18
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$747K, net income −$778K (margin n/a), EPS −$0.17
APUS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$20.2M, EPS −$11.77
- Quarter ended Mar 31, 2026: revenue n/a, net income −$35.1M, EPS −$2.26
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$1.16M, EPS $2.21
- Quarter ended Sep 30, 2025: revenue n/a, net income −$1.78M, EPS −$0.14
- Quarter ended Jun 30, 2025: revenue n/a, net income −$2.66M, EPS −$2.57
- Quarter ended Mar 31, 2025: revenue n/a, net income −$402K, EPS −$0.05
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$312K, EPS −$0.04
- Quarter ended Sep 30, 2024: revenue n/a, net income −$333K, EPS −$0.04
- Quarter ended Jun 30, 2024: revenue n/a, net income −$449K, EPS −$0.06
- Quarter ended Mar 31, 2024: revenue n/a, net income −$296K, EPS −$0.04
APUS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$8.93M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$734K, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$628K, share buybacks n/a
APUS balance sheet
- Jun 30, 2026: cash $278K, total assets $128M, total liabilities $21.2M, shareholders' equity $106M
- Mar 31, 2026: cash $980K, total assets $141M, total liabilities $14.7M, shareholders' equity $127M
- Dec 31, 2025: cash $1.64M, total assets $164M, total liabilities $10.8M, shareholders' equity $153M
- Sep 30, 2025: cash $6.99M, total assets $9.25M, total liabilities $1.09M, shareholders' equity $8.16M
- Jun 30, 2025: cash $8.74M, total assets $10.5M, total liabilities $809K, shareholders' equity $9.74M
- Mar 31, 2025: cash $250K, total assets $260K, total liabilities $2.02M, shareholders' equity −$1.76M
- Dec 31, 2024: cash $3.46K, total assets $13.1K, total liabilities $1.37M, shareholders' equity −$1.36M
- Dec 31, 2023: cash $410K, total assets $422K, total liabilities $390K, shareholders' equity $31.9K
Is APUS profitable?
No. Apimeds Pharmaceuticals US, Inc. lost $58.2M over the last four quarters.
What is APUS's EPS?
Diluted earnings per share over the last four quarters were −$11.96; −$11.77 in the latest quarter.